Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.

Highlight recent updates in lung cancer management, both NSCLC and SCLC. Focus on translational approaches in understanding resistance biology to inform clinical management in patients treated with immuno and targeted therapies Provide the latest update on understanding and use of biomarkers in the tumor macro and microenvironment and circulating in blood Focus on changing concepts and use of immunotherapy and radiotherapy in lung cancer as well as in patients with CNS involvement

Autorentext

Anne Chiang is an Associate Professor at Yale University's School of Medicine and a member of the Yale Cancer Center's Developmental Therapeutics and Thoracic Oncology Programs. She serves as Chief Network Officer and the Deputy Chief Medical Officer at the Smilow Cancer Hospital at Yale. Chiang earned an MD from Weill Cornell Medical College, a Ph.D. in Molecular Genetics from Harvard University and an A.B. from Princeton University in Molecular Biology.

Roy Herbst is the Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology at Yale University's School of Medicine. He serves as Chief of Medical Oncology and the Associate Director for Translational Research at the Yale Cancer Center. Herbst earned his B.S. and M.S. degrees at Yale, his M.D. at Cornell University Medical College and his Ph.D. in Molecular Cell Biology at The Rockefeller University. He has authored more than 275 publications, including peer-reviewedjournal articles, abstracts, and book chapters.

Inhalt

Tumor Microenvironment: Immune Effector and Suppressor Imbalance.- Biomarkers: is tumor mutational burden the new prognostic grail?.- Liquid biopsies: new technology and evidence.- Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance.- What can we learn from acquired resistance?.- Management of Brain Metastases.- Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors.- Therapeutic Advances in Small Cell Lung Cancer Management.- Small Cell Lung Cancer: Biology Advances.- Immunotherapy and Radiotherapy: New Strategies.- Ultimate Precision: Targeting Cancer but not Normal Self-Replication.- Index.